AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30669980 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with poor/fair self-rated health (SRH)
Number of subjects: 134
Study 30669980 — intervention group
Group type: COMPARATOR
Intervention: Caregivers with good, very good, or excellent SRH
Number of subjects: 134
Study 30669980 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with poor/fair SRH
Number of subjects: 134
Study 28833938 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + SOF ± RBV for 12 weeks in genotype 3 infection
Number of subjects: 70
Study 28833938 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + SOF + RBV for 8 weeks in genotype 2 infection
Number of subjects: 70
Study 28833938 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + SOF + RBV for 6 weeks in genotype 2 infection
Number of subjects: 70
Study 26473793 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerostomia patients
Number of subjects: 30
Study 26473793 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 25245446 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide
Number of subjects: 156
Study 25245446 — intervention group
Group type: COMPARATOR
Intervention: ATRA plus chemotherapy
Number of subjects: 156
Study 22357257 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tamoxifen (Tam)
Number of subjects: 153
Study 22357257 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy with adjuvant tamoxifen (Mx + Tam)
Number of subjects: 153
Study 20571433 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine‐XR 225 mg/d
Number of subjects: 150
Study 20571433 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine 45 mg/d
Number of subjects: 150
Study 20571433 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine 20 mg/d
Number of subjects: 150
Study 17174627 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-40
Number of subjects: 1200
Study 17174627 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-70
Number of subjects: 1200
Study 17174627 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR-40
Number of subjects: 1200
Study 17174627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise substudy (minimum of 375 patients)
Number of subjects: 1200
Study 16286163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (up to 80 mg three times daily)
Number of subjects: 84
Study 16286163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 12449085 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 0
Study 12449085 — intervention group
Group type: COMPARATOR
Intervention: Placebo techniques
Number of subjects: 0
Study 12449085 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 9988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (no cortical status spongiosus)
Number of subjects: 14
Study 9988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (with cortical status spongiosus)
Number of subjects: 14
Study 9988133 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study 8854962 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (group I)
Number of subjects: 161
Study 8854962 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (group II)
Number of subjects: 161
Study 2323078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge containing 11 mg L-menthol
Number of subjects: 60
Study 2323078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 499107 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml of 20% glucose per kg body weight (Group II)
Number of subjects: 53
Study 499107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g chloropropamide (Group III)
Number of subjects: 53
Study 499107 — intervention group
Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 53
Study 31100568 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative rib fixation
Number of subjects: 50
Study 28160085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 28160085 — intervention group
Group type: COMPARATOR
Intervention: Interferential current (IFC)
Number of subjects: 40
Study 28160085 — intervention group
Group type: COMPARATOR
Intervention: SHAM placebo
Number of subjects: 40
Study 26781338 — intervention group
Group type: EXPERIMENTAL
Intervention: FospropofolFD 20 mg/kg
Number of subjects: 240
Study 26781338 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 240
Study 25079934 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g dose of cephalexin 30‐60 min before excision
Number of subjects: 52
Study 25079934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21507197 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg dipyrone (D15 group)
Number of subjects: 162
Study 21507197 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg dipyrone (D40 group)
Number of subjects: 162
Study 19730804 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol (400‐4800 mg single dose)
Number of subjects: 0
Study 19730804 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol (3600 mg/day for 7 days)
Number of subjects: 0
Study 19730804 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol (single and multiple doses)
Number of subjects: 0
Study 17312063 — intervention group
Group type: EXPERIMENTAL
Intervention: CT signs of internal hernia (mesenteric swirl, mushroom shape, etc.)
Number of subjects: 18
Study 17312063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of swirled mesentery and mushroom shape
Number of subjects: 18
Study 17312063 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT studies of 18 women without internal hernia)
Number of subjects: 18
Study 15115713 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 100
Study 15115713 — intervention group
Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 100
Study 15115713 — intervention group
Group type: EXPERIMENTAL
Intervention: A77‐1726 (active metabolite of leflunomide)
Number of subjects: 100
Study 12108885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg b.i.d. for 14 days
Number of subjects: 11
Study 12108885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9934937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for up to 12 weeks
Number of subjects: 796
Study 9934937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 796
Study 7557091 — intervention group
Group type: EXPERIMENTAL
Intervention: rHb1.1
Number of subjects: 9
Study 7557091 — intervention group
Group type: COMPARATOR
Intervention: human serum albumin
Number of subjects: 9
Study 2138972 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based cutting fluids
Number of subjects: 23
Study 2138972 — intervention group
Group type: COMPARATOR
Intervention: Neat oils
Number of subjects: 23
Study 2138972 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsifier component of cutting fluids
Number of subjects: 23
Study 2138972 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrosion inhibitor component of cutting fluids
Number of subjects: 23
Study 730419 — intervention group
Group type: EXPERIMENTAL
Intervention: Org GC 94 (45 mg/day for 14 days)
Number of subjects: 16
Study 730419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30907005 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 251
Study 30907005 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 251
Study 28545005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy (TMT)
Number of subjects: 112
Study 26501533 — intervention group
Group type: COMPARATOR
Intervention: naproxen + placebo
Number of subjects: 323
Study 26501533 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen + cyclobenzaprine
Number of subjects: 323
Study 26501533 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen + oxycodone/acetaminophen
Number of subjects: 323
Study 23590237 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interleukin-6 (IL-6) levels
Number of subjects: 650
Study 23590237 — intervention group
Group type: EXPERIMENTAL
Intervention: Most recent IL-6 levels (near time of event)
Number of subjects: 650
Study 23590237 — intervention group
Group type: COMPARATOR
Intervention: Mortality rate
Number of subjects: 650
Study 23590237 — intervention group
Group type: COMPARATOR
Intervention: Causes of death
Number of subjects: 650
Study 23590237 — intervention group
Group type: COMPARATOR
Intervention: Median time to death
Number of subjects: 650
Study 22067848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilotherm
Number of subjects: 90
Study 22067848 — intervention group
Group type: COMPARATOR
Intervention: Conventional cryotherapy
Number of subjects: 90
Study 22067848 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy
Number of subjects: 90
Study 19878089 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236
Study 19878089 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 236
Study 19878089 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 236
Study 15606550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytotoxic treatment and autologous bone marrow transplantation
Number of subjects: 130
Study 15606550 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 130
Study 10568870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucking an unflavored pacifier at a rate exceeding 30 sucks/min
Number of subjects: 10
Study 10568870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sucrose and nonnutritive sucking
Number of subjects: 10
Study 10568870 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures that eliminated crying and reduced heart rate
Number of subjects: 10
Study 8738661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% amino acid dialysis solution (AA-P)
Number of subjects: 18
Study 8738661 — intervention group
Group type: COMPARATOR
Intervention: 1.36% glucose dialysis solution (Glu-P)
Number of subjects: 18
Study 1884189 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning the patients' trunk to the left to compensate for saccadic reaction times (SRTs) towards left visual field (LVF) stimuli.
Number of subjects: 4
Study 1884189 — intervention group
Group type: COMPARATOR
Intervention: Standard body position with midlines of head, trunk, and visual field oriented straight towards the middle of the projection screen.
Number of subjects: 4
Study 7035052 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-adrenergic combination
Number of subjects: 55
Study 7035052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31893580 — intervention group
Group type: EXPERIMENTAL
Intervention: APO(a)‐LRx 20 mg every 4 weeks
Number of subjects: 286
Study 31893580 — intervention group
Group type: EXPERIMENTAL
Intervention: APO(a)‐LRx 40 mg every 4 weeks
Number of subjects: 286
Study 31893580 — intervention group
Group type: EXPERIMENTAL
Intervention: APO(a)‐LRx 20 mg every 2 weeks
Number of subjects: 286
Study 31893580 — intervention group
Group type: EXPERIMENTAL
Intervention: APO(a)‐LRx 60 mg every 4 weeks
Number of subjects: 286
Study 31893580 — intervention group
Group type: EXPERIMENTAL
Intervention: APO(a)‐LRx 20 mg every week
Number of subjects: 286
Study 31893580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 30628573 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention (improved water source, improved household sanitation, handwashing with soap)
Number of subjects: 18
Study 30628573 — intervention group
Group type: COMPARATOR
Intervention: Control (deworming alone)
Number of subjects: 18
Study 29193281 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 61
Study 29193281 — intervention group
Group type: COMPARATOR
Intervention: Control (alanine-supplemented enteral nutrition)
Number of subjects: 61
Study 26842692 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen plus IV narcotics
Number of subjects: 100
Study 26842692 — intervention group
Group type: COMPARATOR
Intervention: IV normal saline plus IV/PO narcotics
Number of subjects: 100
Study 25461785 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face CBT-P
Number of subjects: 52
Study 25461785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure online self-help CBT-P
Number of subjects: 52
Study 25461785 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study 22616822 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced learning schedule
Number of subjects: 36
Study 22616822 — intervention group
Group type: COMPARATOR
Intervention: Massed learning schedule
Number of subjects: 36
Study 22616822 — intervention group
Group type: COMPARATOR
Intervention: Clumped learning schedule
Number of subjects: 36
Study 19856443 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-accelerated autocalibrating parallel reconstruction method for Cartesian sampling (2D-ARC)
Number of subjects: 29
Study 19856443 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRA method
Number of subjects: 29
Study 19856443 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-ARC accelerated MRA
Number of subjects: 29
Study 17222352 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod (local application, q12 applications for 2 or 4 days, or q24 hours for 4 or 8 days)
Number of subjects: 36
Study 17222352 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control group)
Number of subjects: 36
Study 15818652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided local corticosteroid injections (G1 group)
Number of subjects: 68
Study 15818652 — intervention group
Group type: COMPARATOR
Intervention: Standard local corticosteroid injections without ultrasound guidance (G2 group)
Number of subjects: 68
Study 12164331 — intervention group
Group type: EXPERIMENTAL
Intervention: American journals
Number of subjects: 1997
Study 12164331 — intervention group
Group type: COMPARATOR
Intervention: Japanese journals
Number of subjects: 1997
Study 9801954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including leadership support, training on CQI and prevention systems, consultation and networking opportunities
Number of subjects: 57
Study 9801954 — intervention group
Group type: COMPARATOR
Intervention: Comparison clinics received similar assistance
Number of subjects: 57
Study 7697275 — intervention group
Group type: EXPERIMENTAL
Intervention: BA + CS (combined beta 2‐agonist/corticosteroid therapy)
Number of subjects: 274
Study 7697275 — intervention group
Group type: COMPARATOR
Intervention: BA + AC (combined beta 2‐agonist/anticholinergic therapy)
Number of subjects: 274
Study 7697275 — intervention group
Group type: COMPARATOR
Intervention: BA + PL (beta 2‐agonist/placebo therapy)
Number of subjects: 274
Study 7697275 — intervention group
Group type: EXPERIMENTAL
Intervention: BA + CS
Number of subjects: 274
Study 30337747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibia cutting without guide group
Number of subjects: 76
Study 30337747 — intervention group
Group type: COMPARATOR
Intervention: Tibia cutting with extramedullary guide group
Number of subjects: 76
Study 28374186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (vD3) at 3750 U kg‐1, 18,750 U kg‐1, and 37,500 U kg‐1
Number of subjects: 0
Study 28374186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (vD3) at 37,500 U kg‐1
Number of subjects: 0
Study 28374186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (vD3) at various doses
Number of subjects: 0
Study 28374186 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 U kg‐1)
Number of subjects: 0
Study 26564934 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered CISS
Number of subjects: 118
Study 26564934 — intervention group
Group type: COMPARATOR
Intervention: Practitioner-administered CISS
Number of subjects: 118
Study 26564934 — intervention group
Group type: COMPARATOR
Intervention: Normal Binocular Vision (NBV)
Number of subjects: 118
Study 26564934 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency (CI)
Number of subjects: 118
Study 23179148 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stent covered with a paclitaxel-incorporated membrane (MSCPM)
Number of subjects: 106
Study 23179148 — intervention group
Group type: COMPARATOR
Intervention: Covered metal stent (CMS)
Number of subjects: 106
Study 23179148 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCPM
Number of subjects: 106
Study 23179148 — intervention group
Group type: COMPARATOR
Intervention: CMS
Number of subjects: 106
Study 23179148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy
Number of subjects: 106
Study 23179148 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCPM and CMS
Number of subjects: 106
Study 21232139 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of beef as a complementary food for 12 months
Number of subjects: 600
Study 21232139 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient fortified equi‐caloric rice‐soy cereal supplement for 12 months
Number of subjects: 600
Study 21232139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education messages delivered to mothers
Number of subjects: 600
Study 21232139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometry measurements at 6, 9, 12, and 18 months
Number of subjects: 600
Study 21232139 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of iron, zinc, and Vitamin B12 status at 18 months
Number of subjects: 600
Study 21232139 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive development assessments at 12 and 18 months
Number of subjects: 600
Study 21232139 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of infectious morbidity throughout the trial
Number of subjects: 600
Study 18625000 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 22
Study 18625000 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D (control)
Number of subjects: 22
Study 17709062 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture (TrP, n=10)
Number of subjects: 40
Study 17709062 — intervention group
Group type: COMPARATOR
Intervention: Standard acupuncture (SA, n=10)
Number of subjects: 40
Study 17709062 — intervention group
Group type: COMPARATOR
Intervention: Non-trigger point acupuncture (non-TrP, n=10)
Number of subjects: 40
Study 17709062 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (SH, n=10)
Number of subjects: 40
Study 15577425 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (multivitamin plus selenium)
Number of subjects: 400
Study 15577425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 11238476 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine (131I) therapy (4.44 MBq/g thyroid)
Number of subjects: 64
Study 11238476 — intervention group
Group type: COMPARATOR
Intervention: Suppressive levothyroxine treatment aiming at TSH values between 0.01 and 0.1 mU/L
Number of subjects: 64
Study 11238476 — intervention group
Group type: COMPARATOR
Intervention: Suppressive levothyroxine treatment
Number of subjects: 64
Study 9610558 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade
Number of subjects: 3500
Study 9610558 — intervention group
Group type: EXPERIMENTAL
Intervention: Global collaboration and megatrials
Number of subjects: 3500
Study 8113560 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative two-dimensional echocardiography
Number of subjects: 100
Study 8113560 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 8113560 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG criteria for right atrial enlargement
Number of subjects: 100
Study 8113560 — intervention group
Group type: EXPERIMENTAL
Intervention: P pulmonale
Number of subjects: 100
Study 3384075 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 30 mg once daily
Number of subjects: 25
Study 3384075 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 5 mg sustained-release twice daily
Number of subjects: 25
Study 29729588 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine
Number of subjects: 12
Study 29729588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28527625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic micromanipulation (CM)
Number of subjects: 96
Study 28527625 — intervention group
Group type: COMPARATOR
Intervention: Sham (laser assisted zona hatching only)
Number of subjects: 96
Study 28527625 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 96
Study 26711065 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Number of subjects: 63
Study 26711065 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 63
Study 26711065 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 63
Study 23176966 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 92
Study 23176966 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) via popliteal access
Number of subjects: 92
Study 21989724 — intervention group
Group type: EXPERIMENTAL
Intervention: Narafilcon A SCL
Number of subjects: 31
Study 21989724 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A SCL
Number of subjects: 31
Study 18319414 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily
Number of subjects: 15730
Study 18319414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15730
Study 16563608 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic prostatectomy (LRP)
Number of subjects: 120
Study 16563608 — intervention group
Group type: COMPARATOR
Intervention: Open radical retropubic prostatectomy (RRP)
Number of subjects: 120